Results 211 to 220 of about 115,090 (246)

Engineering a 660 nm‐Responsive Optogenetic Inducer of Pyroptosis for Precision Cancer Therapy

Advanced Science, EarlyView.
This study reports a bioorthogonal pyroptosis inducer, PyroRACS. By using a red‐light‐responsive Cre‐On genetic switch to control the expression of highly cytotoxic GSDMDNT, PyroRACS enables the artificial induction of pyroptosis with precise spatiotemporal control.
Mengkai Zhang, Zhichao Li, Yonghao Ma, Yangyang Sun, Wei Chen, Weiren Huang   +5 more
wiley   +1 more source

Nanovesicles With Mechanically Induced Adjuvanticity for Robust Melanoma Vaccination Toward Tumor‐Associated Macrophages

Advanced Science, EarlyView.
Rigidity‐tunable nanovesicle (P‐Pm) with mechanically induced adjuvanticity toward tumor‐associated macrophages (TAMs) was designed to engineer R848/gp100 antigen ‐loaded nanovaccine (P@Rg‐Pm), which achieved outstanding anti‐tumor outcomes in both therapeutic and preventive model of B16‐F10 melanoma.
Bangyue Luo, Liyan Qiu
wiley   +1 more source

A High‐Loading Zn Single‐Atom Nanozyme Targets the Zn/HIF‐1α/GLUT1 Axis to Disrupt Glucose Metabolic Reprogramming and Remodel the Tumor Immune Microenvironment

Advanced Science, EarlyView.
A high‐loading Zn single‐atom nanozyme (ZMG@CS) delivers ML‐SA5 and GOx to lysosomes. ML‐SA5 activates TRPML1 to release endogenous Zn2+, while the nanozyme provides exogenous Zn2+ and GOx‐driven acidification amplifies ROS production. Together, these effects suppress the HIF‐1α/GLUT1 axis, disrupt glucose and redox homeostasis, induce disulfidptosis ...
Zhenxin Wang, Yuhang Tang, Ronghao Yue, Jingtao Xu, Yong Tao, Jie Chen, Shipeng Li, Guosheng Zhao, Jinfang Xue, Mingwei Sun, Fenglei Gao, Yunsheng Ou, Yang Wang   +12 more
wiley   +1 more source

BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer

Advanced Science, EarlyView.
BCG‐derived HSP70 (Dnak) safely induces central trained immunity via epigenetic, metabolic, and O‐GlcNAcylation reprogramming of bone marrow progenitors, driving tumor‐associated macrophages toward an M1‐like phenotype to suppress prostate cancer. ABSTRACT Trained immunity offers a promising yet clinically challenging strategy for cancer immunotherapy,
Peng Liu, Kangkang Liu, Keruo Wang, Heyang Guan, Jiaming Fan, Taipeng Li, Jiaru Hao, Zeyuan Wang, Yongchao Yan, Jiatong Chen, Yuan Ma, Yang Yang, Yuanjie Niu   +12 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cancer Immunotherapy with Cytokine-Induced Killer Cells

Targeted Oncology, 2017
Cytokine-induced killer (CIK) cells form under certain stimulation conditions in cultures of peripheral blood mononuclear cells (PBMCs). They are a heterogeneous immune cell population and contain a high percentage of cells with a mixed T-NK phenotype (CD3+CD56+).
Juan J, Mata-Molanes, Manuel, Sureda González, Belén, Valenzuela Jiménez, Elena Mª, Martínez Navarro, Antonio, Brugarolas Masllorens   +4 more
openaire   +2 more sources

Is there a Role for Cytokine-Induced Killer Cells in Cancer Immunotherapy?

Immunotherapy, 2012
867 ISSN 1750-743X 10.2217/IMT.12.89 © 2012 Future Medicine Ltd Immunotherapy (2012) 4(9), 867–869 “There is no doubt that the use of cytokine-induced killer cells holds promise but only the future will tell us whether this relatively simple form of adoptive cellular immunotherapy will really have an impact on the still dismal prognosis of patients ...
Rutella, Sergio, Locatelli, Franco
openaire   +2 more sources

Promising immunotherapy: Highlighting cytokine‐induced killer cells

Journal of Cellular Biochemistry, 2018
AbstractFor many years, cancer therapy has appeared to be a challenging issue for researchers and physicians. By the introduction of novel methods in immunotherapy, the prospect of cancer therapy even more explained than before. Cytokine‐induced killer (CIK) cell‐based immunotherapy demonstrated to have potentiality in improving clinical outcomes and ...
Solmaz Shirjang, Nazila Alizadeh, Behzad Mansoori, Ata Mahmoodpoor, Hossein Samadi Kafil, Mohammad Hojjat‐Farsangi, Mehdi Yousefi   +6 more
openaire   +2 more sources

Activated T cells and cytokine-induced CD3 + CD56 + killer cells

Annals of Hematology, 1997
Over the past two decades, attempts have been made to develop immunotherapy for patients with cancer. A significant obstacle to the development of successful adoptive immunotherapy has been the availability of appropriate cytotoxic cells. Immunologic effector cells such as lymphokine-activated killer (LAK) cells, activated T cells such as tumor ...
Schmidt-Wolf I G H, I G Schmidt-Wolf, R S Negrin   +2 more
exaly   +3 more sources

Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms

Immunology Letters, 2013
Cytokine Induced Killer (CIK) cells are in vitro activated human CD8 T cells which have maintained several characteristics of T-EMRA cells and additionally acquired non specific anti tumoral cytotoxicity and CD56 overexpression, thus representing a cell population with double T and NK phenotype.
Martino Introna, Alessandro Rambaldi
exaly   +3 more sources

Immunotherapy with Cytokine-Induced Killer Cells in Metastatic Renal Cell Carcinoma

Cancer Biotherapy and Radiopharmaceuticals, 2010
Cytokine-induced killer (CIK) cells have shown antitumor activity against several tumor cells both in vitro and in vivo. This study reports on the large-scale expansion of CIK cells and also present preliminary results from a pilot clinical trial.
Xiaosan, Su, Lei, Zhang, Liangkun, Jin, Junsong, Ye, Zheng, Guan, Rui, Chen, Tao, Guo   +6 more
openaire   +2 more sources